Taipei, Taiwan

Steven R Roffler

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 5.9

ph-index = 1


Location History:

  • Kaohsiung, TW (2016)
  • Taipai, TW (2019)
  • Taipei, TW (2021 - 2022)

Company Filing History:


Years Active: 2016-2022

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Steven R Roffler

Introduction

Steven R Roffler is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of bi-specific antibodies, particularly in their application for cancer treatment. With a total of four patents to his name, Roffler's work is at the forefront of innovative medical research.

Latest Patents

Roffler's latest patents focus on bi-specific antibodies that specifically direct therapeutic agents to cancer cells. These antibodies target tumor antigens, effectively suppressing cancer growth and blocking invasion or metastasis. The bi-specific antibodies include a first antigen binding site that binds to polyethylene glycol (PEG) and a second antigen binding site that binds to a target ligand, such as a tumor antigen. This innovative approach has the potential to revolutionize cancer treatment.

Career Highlights

Throughout his career, Roffler has worked with prestigious institutions such as Kaohsiung Medical University and Academia Sinica. His research has garnered attention for its potential impact on cancer therapies and has contributed to advancements in the field of immunology.

Collaborations

Roffler has collaborated with notable colleagues, including Tian-Lu Cheng and Kuo-Hsiang Chuang. These partnerships have further enhanced the scope and depth of his research, leading to significant advancements in bi-specific antibody technology.

Conclusion

Steven R Roffler's innovative work in bi-specific antibodies showcases his commitment to advancing cancer treatment. His contributions to the field are invaluable and highlight the importance of continued research in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…